In fact, acquired resistance to gefitinib, an EGFR tyrosine kinase inhibitor, can be mediated by MET amplification in patients with non-small cell lung cancer (NSCLC)[18, 19]. The gene discussed is MET; the disease is non-small cell lung carcinoma.